DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Guselkumab
Guselkumab
WHO Drug Information Vol
Inflammatory Conditions – Kevzara™ (Sarilumab for Subcutaneous Injection)
New Biologics in Psoriasis: an Update on IL-23 and IL-17 Inhibitors
Emerging Therapies in Psoriasis: a Systematic Review
Immunfarmakológia Immunfarmakológia
(12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
WO 2016/176089 Al 3 November 2016 (03.11.2016) P O P C T
Protocol I1F-MC-RHCR
Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis Based on the ECLIPSE Trial
1 HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do
Efficacy and Safety of Guselkumab, an Anti–Interleukin 23 Monoclonal
Guselkumab, Ixekizumab and Secukinumab for Treating Chronic Plaque Psoriasis Technology Guidance from the MOH Drug Advisory Committee
IL-23 Inhibitors
2017 New Drug Update
Inflammatory Conditions – Ilaris® (Canakinumab for Subcutaneous Injection)
Guselkumab (Tremfya) Reference Number: ERX.SPA.217 Effective Date: 12.01.17 Last Review Date: 05.21 Line of Business: Commercial, Medicaid Revision Log
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
CDER List of Licensed Biological Products With
Top View
(INN) for Biological and Biotechnological Substances
Guselkumab Induces Robust Reduction in Acute Phase Proteins and Type 17 Effector Cytokines in Active Psoriatic Arthritis: Results from Phase 3 Trials
Anti-IL-4Rα (Dupilumab), Human Igg4 Antibody
Actemra SC ® (Tocilizumab) Prior Approval Is Required for Some Or All
July 2017 a View Into Upcoming Specialty and Traditional Drugs TABLE of CONTENTS
WO 2018/013551 Al 18 January 2018 (18.01.2018) W !P O PCT
Planning for the 2017 Specialty Drug Spend When Costs Are Steep but Pockets Are Not Deep
Tocilizumab Intravenous – (M0004)
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
TREMFYA (Guselkumab) Injection, for Subcutaneous Use • Tuberculosis (TB): Evaluate for TB Prior to Initiating Treatment with Initial U.S
New Drug Evaluation Monograph Template
Annrheumdis-2019-216653.Full.Pdf
Comparative Cost-Effectiveness of Tildrakizumab and Other Commonly Used Treatments for Moderate-To-Severe Psoriasis
Utah Medicaid Pharmacy and Therapeutics Committee Drug
Use of Guselkumab for the Treatment of Moderate-To-Severe Plaque Psoriasis: a 1 Year Real-Life Study
Inflammatory Conditions – Tremfya® (Guselkumab for Subcutaneous Injection)
Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies
Psoriatic Arthritis Agents
Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: an Updated Systematic Review and Meta-Analysis
Development of Sézary Syndrome Following the Administration of Dupilumab
Three-Year Clinical Efficacy of Guselkumab and Ixekizumab in Moderate-To-Severe Plaque Psoriasis: a Matching-Adjusted Indirect Comparison
COVID-19 Vaccine Clinical Guidance Summary for Patients with Rheumatic and Musculoskeletal Diseases
Annual Report 2017 Morphosys AG Annual Report Product Pipeline Morphosys’S Product Pipeline (March 8, 2018)
Policy: 201703 Initial Effective Date: 02/14/2017 HCPCS J0638 Code(S): Annual Review Date: 10/15/2020
Guselkumab: an Anti-IL-23 Antibody for the Treatment of Moderate-To
Tremfya (Guselkumab) NOTICE
Susceptibility and Severity of COVID-19 in Patients Treated With
Guselkumab for Treating Active Psoriatic Arthritis After Inadequate Response to Dmards
Esophagitis: Drugs Picture of Iron Pill Material in Biopsy TT’S Kodachrome 1St Page Folder Iron Medication Injury Medications/Drugs
Guselkumab) Injection, for Subcutaneous Use Serious Hypersensitivity Reactions to Guselkumab Or to Any of the Excipients
Versus TREMFYA® (Guselkumab)
(INN) for Biological and Biotechnological Substances
761067Orig1s000
Self-Administered Drugs Code List 2019
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies
Cimzia® (Certolizumab Pegol) – Oxford Clinical Policy
PDCO Monthly Report of Opinions on Paediatric Investigation Plans and Other Activities 23-26 June 2020
CV Blauvelt March 2021
Severe Plaque Psoriasis: Effectiveness and Value
Population Pharmacokinetics of the Interleukin-23 Inhibitor
Immune Modulating Therapies for Rheumatologic, Dermatologic and Gastrointestinal Diseases
Certolizumab Pegol for Treating Moderate to Severe Plaque Psoriasis
A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 In
Tremfya, INN-Guselkumab
Cytokine and CAM Antagonists
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri
Risk of Infection Associated with Biological Agents Used for Autoimmune Inflammatory Diseases
Antibodies to Watch in 2018